EOC
MCID: OVR094
MIFTS: 38

Ovarian Epithelial Cancer (EOC)

Categories: Cancer diseases, Rare diseases

Aliases & Classifications for Ovarian Epithelial Cancer

MalaCards integrated aliases for Ovarian Epithelial Cancer:

Name: Ovarian Epithelial Cancer 52 29 6
Epithelial Ovarian Cancer 52 71
Ovarian Epithelial Carcinoma 52
Ovarian Cancer, Epithelial 52
Eoc 52

Classifications:



External Ids:

UMLS 71 C0677886

Summaries for Ovarian Epithelial Cancer

MalaCards based summary : Ovarian Epithelial Cancer, also known as epithelial ovarian cancer, is related to ovarian cancer and malignant epithelial tumor of ovary. An important gene associated with Ovarian Epithelial Cancer is PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha). The drugs Dexamethasone acetate and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include ovary, t cells and breast.

Related Diseases for Ovarian Epithelial Cancer

Diseases related to Ovarian Epithelial Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 299)
# Related Disease Score Top Affiliating Genes
1 ovarian cancer 28.2 PIK3CA ERLNC1 DNM3OS CERNA2 CCAT2 CCAT1
2 malignant epithelial tumor of ovary 11.8
3 primary peritoneal carcinoma 11.6
4 ovarian clear cell carcinoma 11.6
5 ovary transitional cell carcinoma 11.3
6 alopecia 10.5
7 fallopian tube carcinoma 10.5
8 neuropathy 10.5
9 peripheral nervous system disease 10.5
10 thrombocytosis 10.5
11 thrombocytopenia 10.5
12 clear cell adenocarcinoma 10.4
13 ovarian disease 10.4
14 mucinous adenocarcinoma 10.4
15 mucinous cystadenocarcinoma 10.4
16 appendix adenocarcinoma 10.4
17 ileus 10.4
18 infertility 10.3
19 severe combined immunodeficiency 10.3
20 47,xyy 10.3
21 insulin-like growth factor i 10.3
22 body mass index quantitative trait locus 1 10.3
23 cytokine deficiency 10.3
24 ovarian serous carcinoma 10.3
25 sensory peripheral neuropathy 10.3
26 lynch syndrome 10.3
27 stomatitis 10.3
28 granulocytopenia 10.3
29 familial ovarian cancer 10.3
30 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.2
31 pelvic inflammatory disease 10.2
32 endometriosis of ovary 10.2
33 constipation 10.2
34 ovarian cystadenoma 10.2
35 b-cell lymphoma 10.2
36 acute sensory ataxic neuropathy 10.2
37 colorectal cancer 10.2
38 body mass index quantitative trait locus 11 10.2
39 epileptic encephalopathy, childhood-onset 10.2
40 diarrhea 10.2
41 adenoma 10.2
42 48,xyyy 10.2
43 breast cancer 10.2
44 retinoblastoma 10.2
45 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 10.2
46 body mass index quantitative trait locus 9 10.2
47 body mass index quantitative trait locus 8 10.2
48 body mass index quantitative trait locus 4 10.2
49 body mass index quantitative trait locus 10 10.2
50 body mass index quantitative trait locus 7 10.2

Graphical network of the top 20 diseases related to Ovarian Epithelial Cancer:



Diseases related to Ovarian Epithelial Cancer

Symptoms & Phenotypes for Ovarian Epithelial Cancer

Drugs & Therapeutics for Ovarian Epithelial Cancer

Drugs for Ovarian Epithelial Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 393)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
2
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
3
Olaparib Approved Phase 4 763113-22-0 23725625
4
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
5 Gastrointestinal Agents Phase 4
6 Poly(ADP-ribose) Polymerase Inhibitors Phase 4
7 Antirheumatic Agents Phase 4
8 Analgesics Phase 4
9 Analgesics, Non-Narcotic Phase 4
10 Cyclooxygenase Inhibitors Phase 4
11 Anti-Inflammatory Agents Phase 4
12 Anti-Inflammatory Agents, Non-Steroidal Phase 4
13 Platelet Aggregation Inhibitors Phase 4
14 Antipyretics Phase 4
15
Melphalan Approved Phase 3 148-82-3 460612 4053
16
Sodium citrate Approved, Investigational Phase 3 68-04-2
17
Trabectedin Approved, Investigational Phase 3 114899-77-3 108150
18
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
19
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
20
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
21
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
22
Ondansetron Approved Phase 3 99614-02-5 4595
23
Pertuzumab Approved Phase 3 380610-27-5, 145040-37-5 2540
24
Captopril Approved Phase 3 62571-86-2 44093
25
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
26
Ribavirin Approved Phase 3 36791-04-5 37542
27
Palivizumab Approved, Investigational Phase 3 188039-54-5
28
Acyclovir Approved Phase 3 59277-89-3 2022
29
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 2826718 468682
30
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
31
Rucaparib Approved, Investigational Phase 3 283173-50-2 9931954
32
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
33
Bevacizumab Approved, Investigational Phase 3 216974-75-3
34
Gemcitabine Approved Phase 3 95058-81-4 60750
35
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 43805 6857599 5310940 9887054
36
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
37
Atezolizumab Approved, Investigational Phase 3 1380723-44-3
38
Adenosine Approved, Investigational Phase 3 58-61-7 60961
39
Talazoparib Approved, Investigational Phase 3 1207456-01-6 135565082
40
Ropivacaine Approved Phase 3 84057-95-4 71273 175805
41
Letrozole Approved, Investigational Phase 3 112809-51-5 3902
42
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
43
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
44
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
45
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
46
Moxifloxacin Approved, Investigational Phase 3 354812-41-2, 151096-09-2 152946
47
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
48
Polyestradiol phosphate Approved Phase 3 28014-46-2
49
Mycophenolic acid Approved Phase 3 24280-93-1 446541
50
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311

Interventional clinical trials:

(show top 50) (show all 915)
# Name Status NCT ID Phase Drugs
1 A MULTICENTER STUDY IN PATIENTS WITH STAGE III-IV EPITHELIAL OVARIAN CANCER TREATED WITH CARBOPLATIN/PACLITAXEL WITH BEVACIZUMAB: CLINICAL AND BIOLOGICAL PROGNOSTIC FACTORS Unknown status NCT01706120 Phase 4 Bevacizumab;Paclitaxel;Carboplatin
2 Obligatory Post-Registration Open-Label, Non-Comparative Multicenter Study of Efficacy and Tolerance Rate of Caelyx as Monotherapy in Patients With Epithelial Ovarian Cancer, Resistant to Previous Platinum Therapy. Completed NCT00727961 Phase 4 Pegylated Liposomal Doxorubicin hydrochloride
3 Tumor Gene Expression Before and After Intraoperative Dexamethasone in Women With Ovarian Cancer Completed NCT00817479 Phase 4 Dexamethasone;Placebo
4 Evaluation of PEGylated Doxorubicin Hydrochloride Liposome Injection(Duomeisu®) Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer: A Randomized, Open, Multicenter Clinical Study Recruiting NCT03794778 Phase 4 pegylated liposomal doxorubicin;paclitaxel;Carboplatin
5 A Prospective, Multicentre, Phase-IV Clinical Trial of Olaparib in Indian Patients With Platinum Sensitive Relapsed Ovarian Cancer Who Are in Complete or Partial Response Following Platinum Based Chemotherapy and Metastatic Breast Cancer With Germline BRCA1/2 Mutation Recruiting NCT04330040 Phase 4 Olaparib
6 Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib in Maintenance After Platine-based Chemotherapy for Patients With Ovarian Cancer Late Relapse : the French GINECO - NiQoLe Study Recruiting NCT03752216 Phase 4 Niraparib
7 An Open Label, Single Arm, Multicentre Study to Assess the Clinical Effectiveness and Safety of Lynparza (Olaparib) Capsules Maintenance Monotherapy in Platinum Sensitive Relapsed Somatic or Germline BRCA Mutated Ovarian Cancer Patients Who Are in Complete or Partial Response Following Platinum Based Chemotherapy (ORZORA). Active, not recruiting NCT02476968 Phase 4 Olaparib
8 Aspirin for Prevention of Venous Thromboembolism Among Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy Not yet recruiting NCT04352439 Phase 4 Aspirin
9 Contrast Enhanced Diffusion-weighted Magnetic Resonance Imaging for Detection of Pathologic Lymph Nodes in Ovarian Cancer - a Feasibility Study. Withdrawn NCT02243059 Phase 4 Gadofosveset trisodium (Ablavar™ )
10 Multicenter Randomized Survival Study of Monoclonal Antibody Radioimmunotherapy: A Multinational Study in Patients With Ovarian Carcinoma Using the HMFG1 Antibody Labeled With 90Yttrium Unknown status NCT00004115 Phase 3
11 An International Phase III Randomised Trial of Dose Fractionated Chemotherapy Compared to Standard Three Weekly Chemotherapy, Following Immediate Primary Surgery or as Part of Delayed Primary Surgery, for Women With Newly Diagnosed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Unknown status NCT01654146 Phase 3 Carboplatin;Carboplatin;Paclitaxel;Paclitaxel
12 Neoadjuvant Chemotherapy (NACT) Followed by Interval Debulking Surgery vs Upfront Surgery Followed by Chemotherapy (CT) in Advanced Epithelial Ovarian Carcinoma (EOC): A Prospective Randomized Study Unknown status NCT00715286 Phase 3
13 Phase III Randomized Study of Adjuvant Therapy With a Platinum-Containing Regimen (e.g., CBDCA or CAP: CTX/DOX/CDDP) vs No Adjuvant Therapy in Patients With Fully Resected Early Stage Ovarian Cancer Unknown status NCT00002477 Phase 3 carboplatin;cisplatin;cyclophosphamide;doxorubicin hydrochloride
14 Randomized Double-Blind Controlled Phase III Trial of Hyperbaric Oxygen Therapy in Patients Suffering Long-Term Adverse Effects of Radiotherapy for Pelvic Cancer (HOT II) Unknown status NCT01087268 Phase 3
15 A Randomized Phase II/III Trial Comparing Carboplatin-Ifosfamide (IC)-Chemotherapy Vs. IC-Chemotherapy Combined With Extreme Whole Body Hyperthermia In Patients With Recurrence Of Epithelial Ovarian Carcinoma: DOLPHIN-1-STUDY Unknown status NCT00045461 Phase 2, Phase 3 carboplatin;ifosfamide
16 Multicenter Phase III Randomized Study With Second Line Chemotherapy Plus or Minus Bevacizumab in Patients With Platinum Sensitive Epithelial Ovarian Cancer Recurrence After a Bevacizumab/Chemotherapy First Line Unknown status NCT01802749 Phase 3 Bevacizumab;Paclitaxel;Carboplatin;pegylated liposomal doxorubicin;Gemcitabine
17 A Randomised, Placebo-controlled, Trial of Concurrent Cediranib [AZD2171] (With Platinum-based Chemotherapy) and Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer Unknown status NCT00532194 Phase 3 cediranib
18 Phase III Randomized Multicentre Trial of Carboplatin + Liposomal Doxorubicin vs Carboplatin + Paclitaxel in Patients With Ovarian Cancer Unknown status NCT00326456 Phase 3 liposomal doxorubicin;carboplatin;paclitaxel
19 Phase III Multicenter Study in Epithelial Ovarian Carcinoma FIGO Stage IIB-IV Comparing Treatment With Paclitaxel and Carboplatin to Paclitaxel and Carboplatin Sequentially Followed by Topotecan Completed NCT00006454 Phase 3 carboplatin;paclitaxel;topotecan hydrochloride
20 A Randomized, Prospective Phase III Comparison of Paclitaxel-Carboplatin Versus Docetaxel-Carboplatin as First Line Chemotherapy in Stage Ic-IV Epithelial Ovarian Cancer Completed NCT00003998 Phase 3 carboplatin;docetaxel;paclitaxel
21 A PHASE III RANDOMIZED STUDY OF CISPLATIN (NSC #119875) AND TAXOL (PACLITAXEL) (NSC #125973) WITH INTERVAL SECONDARY CYTOREDUCTION VERSUS CISPLATIN AND PACLITAXEL IN PATIENTS WITH SUBOPTIMAL STAGE III & IV EPITHELIAL OVARIAN CARCINOMA Completed NCT00002568 Phase 3 cisplatin;paclitaxel
22 A Multi-National Randomized Phase-III GCIG Intergroup-Study Comparing 1st-line Chemotherapy With Gemcitabine/Paclitaxel/Carboplatin vs Paclitaxel/Carboplatin In Previously Untreated Patients With Epithelial Ovarian Cancer FIGO Stages I-IV Completed NCT00052468 Phase 3 TCG;TC
23 ICON7 - A Randomised, Two-Arm, Multi-Centre Gynaecologic Cancer InterGroup Trial of Adding Bevacizumab to Standard Chemotherapy (Carboplatin and Paclitaxel) in Patients With Epithelial Ovarian Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
24 A Randomized Phase III Study Comparing Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Epithelial Ovarian Carcinoma Who Failed First-Line Platinum-Based Therapy Completed NCT00006453 Phase 3 carboplatin;gemcitabine hydrochloride
25 A Randomized Study Of Tamoxifen Versus Thalidomide (NSC# 66847) In Patients With Biochemical-Recurrence-Only Epithelial Ovarian Cancer, Cancer Of The Fallopian Tube, And Primary Peritoneal Carcinoma After First Line Chemotherapy Completed NCT00041080 Phase 3 tamoxifen citrate;thalidomide
26 A Randomised Trial of Interval Debulking Surgery in Epithelial Ovarian Cancer Suboptimally Debulked at Primary Surgery Completed NCT00003695 Phase 3 chemotherapy
27 A Phase III Randomized Trial of Cisplatin (NSC #119875) With Paclitaxel (NSC #125973) Administered by Either 24 Hour Infusion or 96 Hour Infusion in Patients With Selected Stage III and Stage IV Epithelial Ovarian Cancer and Primary Peritoneal Carcinoma Completed NCT00002717 Phase 3 cisplatin;paclitaxel
28 A Phase III Randomized Trial of Intravenous Paclitaxel and Cisplatin Versus Intravenous Paclitaxel, Intraperitoneal Cisplatin and Intraperitoneal Paclitaxel in Patients With Optimal Stage III Epithelial Ovarian Carcinoma or Primary Peritoneal Carcinoma Completed NCT00003322 Phase 3 cisplatin;paclitaxel
29 A Phase III Study of Cisplatin Plus Topotecan Followed by Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Carboplatin as First Line Chemotherapy in Women With Newly Diagnosed Advanced Epithelial Ovarian Cancer Completed NCT00028743 Phase 3 carboplatin;cisplatin;paclitaxel;topotecan hydrochloride
30 A Phase 3 Study of Safety and Efficacy of Karenitecin Versus Topotecan Administered for 5 Consecutive Days Every 3 Weeks in Patients With Advanced Epithelial Ovarian Cancer Completed NCT00477282 Phase 3 Karenitecin;Topotecan
31 Multi-Center, Randomized, Double-Blind, Phase III Efficacy Study Comparing Phenoxodiol in Combination With Carboplatin Versus Carboplatin With Placebo in Patients With Platinum-Resistant or Platinum-Refractory Late-Stage Epithelial Ovarian, Fallopian or Primary Peritoneal Cancer Following at Least Second Line Platinum Therapy Completed NCT00382811 Phase 3 phenoxodiol;carboplatin;placebo
32 Amifostine as a Toxicity Protectant in Ovarian Cancer in Chemotherapy Treated Patients: A Pilot Phase III Randomized Controlled Trial Completed NCT00004166 Phase 3 amifostine trihydrate
33 A Randomized Phase III Study Comparing Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Epithelial Ovarian Carcinoma Who Failed First-Line Platinum-Based Therapy Completed NCT00102414 Phase 3 Gemcitabine
34 Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer Completed NCT00850772 Phase 3
35 FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer Completed NCT02631876 Phase 3 Mirvetuximab soravtansine;Paclitaxel;Pegylated liposomal doxorubicin;Topotecan
36 A Randomized Phase III Trial of Sequential High Dose Chemotherapy or Standard Chemotherapy for Optimally Debulked FIGO Stage III and IV Ovarian Cancer Completed NCT00004921 Phase 3 carboplatin;cyclophosphamide;melphalan;paclitaxel
37 Phase III Randomized Study of TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Liposomal Doxorubicin (Doxil) as Second-Line Therapy in Platinum Refractory or Resistant Ovarian Cancer [ASSIST-3] Completed NCT00102973 Phase 3 TLK286 in Combination with Carboplatin;Doxorubicin HCl Liposome Injection
38 SCOTROC 4: A Prospective, Multicentre, Randomised Trial Of Carboplatin Flat Dosing Vs Intrapatient Dose Escalation In First Line Chemotherapy Of Ovarian, Fallopian Tube And Primary Peritoneal Cancers Completed NCT00098878 Phase 3 carboplatin
39 A Randomized Feasibility Trial to Determine the Impact of Timing of Surgery and Chemotherapy in Newly Diagnosed Patients With Advanced Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Carcinoma Completed NCT00075712 Phase 2, Phase 3 carboplatin;paclitaxel
40 A Randomized, Multicenter, Phase III Study of Erlotinib Versus Observation in Patients With no Evidence of Disease Progression After First Line, Platinum-Based Chemotherapy For High-Risk Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00263822 Phase 3 erlotinib hydrochloride
41 A Multi-National,Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin and Carboplatin Versus Paclitaxel and Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse (> 6 Months) Completed NCT00189553 Phase 3 Pegylated liposomal doxorubicin;Carboplatin;Paclitaxel
42 A Randomized Phase III Double-Blind Study Of Ondansetron And Dexamethasone Versus Ondansetron And Placebo In The Prophylaxis Of Radiation-Induced Emesis Completed NCT00016380 Phase 3 dexamethasone;ondansetron
43 A Randomized Phase III Trial of IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q 21 Days x 3 Courses Plus Low Dose Paclitaxel 40 mg/m2/wk Versus IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q 21 Days x 3 Courses Plus Observation in Patients With Early Stage Ovarian Carcinoma Completed NCT00003644 Phase 3 carboplatin;paclitaxel
44 Phase III Randomized Trial of 12 Months vs. 3 Months of Paclitaxel in Patients With Advanced Ovarian Cancer Who Attain a Clinically Defined Complete Response (CR) Following Platinum/Paclitaxel-Based Chemotherapy Completed NCT00003120 Phase 3 paclitaxel
45 A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy Completed NCT00043082 Phase 3 carboplatin;pegylated liposomal doxorubicin hydrochloride
46 A Randomized, Parallel Group, Open-label, Active Controlled, Multicenter Phase III Trial of Patupilone (EPO906) Versus Pegylated Liposomal Doxorubicin in Taxane/Platinum Refractory/Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian or Primary Peritoneal Cancer Completed NCT00262990 Phase 3 EPO906 (Patupilone);doxorubicin
47 Global Study to Assess the Addition of Bevacizumab to Carboplatin and Paclitaxel as Front-line Treatment of Epithelial Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma Completed NCT01239732 Phase 3 Paclitaxel;Bevacizumab;Carboplatin
48 Randomized Trial on Chemosensitivity Testing in Advanced Primary Ovarian Carcinoma (Phase III) Completed NCT00003214 Phase 3 carboplatin;cisplatin;cyclophosphamide;doxorubicin hydrochloride;in vitro sensitivity-directed chemotherapy;paclitaxel
49 A RANDOMISED TRIAL OF PACLITAXEL (TAXOL) IN COMBINATION WITH PLATINUM CHEMOTHERAPY VS. CONVENTIONAL PLATINUM-BASED CHEMOTHERAPY IN THE TREATMENT OF WOMEN WITH RELAPSED OVARIAN CANCER Completed NCT00002894 Phase 3 carboplatin;cisplatin;paclitaxel
50 A Two-Part, Randomized Phase III, Double-Blind, Multicenter Trial Assessing The Efficacy And Safety of Pertuzumab In Combination With Standard Chemotherapy Vs. Placebo Plus Standard Chemotherapy In Women With Recurrent Platinum-Resistant Epithelial Ovarian Cancer And Low HER3 mRNA Expression Completed NCT01684878 Phase 3 Gemcitabine (Chemotherapy);Paclitaxel (Chemotherapy);Pertuzumab;Placebo;Topotecan (Chemotherapy)

Search NIH Clinical Center for Ovarian Epithelial Cancer

Genetic Tests for Ovarian Epithelial Cancer

Genetic tests related to Ovarian Epithelial Cancer:

# Genetic test Affiliating Genes
1 Ovarian Epithelial Cancer 29

Anatomical Context for Ovarian Epithelial Cancer

MalaCards organs/tissues related to Ovarian Epithelial Cancer:

40
Ovary, T Cells, Breast, Testes, Lymph Node, Endothelial, Bone

Publications for Ovarian Epithelial Cancer

Articles related to Ovarian Epithelial Cancer:

(show top 50) (show all 9439)
# Title Authors PMID Year
1
Serum miR-125b levels associated with epithelial ovarian cancer (EOC) development and treatment responses. 61
32107956 2020
2
Electrochemical immunomagnetic assay as biosensing strategy for determination of ovarian cancer antigen HE4 in human serum. 61
32498877 2020
3
BRCA immunohistochemistry for screening of BRCA mutation in epithelial ovarian cancer patients. 61
32529018 2020
4
IGF1R Axis Inhibition Restores Dendritic Cell Antitumor Response in Ovarian Cancer. 61
32428851 2020
5
Prediagnosis and postdiagnosis smoking and survival following diagnosis with ovarian cancer. 61
31693173 2020
6
Clinical significance of CD38 and CD101 expression in PD-1+CD8+ T cells in patients with epithelial ovarian cancer. 61
32565998 2020
7
Apomorphine facilitates loss of respiratory chain activity in human epithelial ovarian cancer and inhibits angiogenesis in vivo. 61
32437927 2020
8
Long non-coding RNA NPBWR1-2 affects the development of ovarian cancer via multiple microRNAs. 61
32565993 2020
9
Epithelial ovarian cancer: a review of preoperative imaging features indicating suboptimal surgery. 61
32347021 2020
10
Cytokine mRNA and protein expression by cell cultures of epithelial ovarian cancer-Methodological considerations on the choice of analytical method for cytokine analyses. 61
32307767 2020
11
First-Line Management of Advanced High-Grade Serous Ovarian Cancer. 61
32494876 2020
12
Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer. 61
32560564 2020
13
Suppressive activities of mangiferin on human epithelial ovarian cancer. 61
32570111 2020
14
A healthy lifestyle and survival among women with ovarian cancer. 61
32542708 2020
15
Prognostic value of radiological recurrence patterns in ovarian cancer. 61
32171567 2020
16
Differential blood count as triage tool in evaluation of pelvic masses. 61
32487682 2020
17
Interval debulking surgery is not worth the wait: a National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy. 61
32341114 2020
18
Diagnostic Value of Risk of Malignancy Algorithm (ROMA) in Adnexal Masses. 61
32476768 2020
19
[Are there still indications of lymph node dissection in epithelial ovarian cancers after the LION trial?] 61
31587803 2020
20
Decoding molecular interplay between RUNX1 and FOXO3a underlying the pulsatile IGF1R expression during acquirement of chemoresistance. 61
32142859 2020
21
Favorable prognostic impact of Natural Killer cells and T cells in high-grade serous ovarian carcinoma. 61
31931651 2020
22
Eupatilin Promotes Cell Death by Calcium Influx through ER-Mitochondria Axis with SERPINB11 Inhibition in Epithelial Ovarian Cancer. 61
32503295 2020
23
Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study. 61
32275468 2020
24
Impact of Lymph Node Sampling in Stage II and III Epithelial Ovarian Cancer Patients with Clinically Negative Lymph Nodes. 61
32523262 2020
25
Lymphocytic infiltration and Chemotherapy Response Score as prognostic markers in ovarian cancer patients treated with Neoadjuvant chemotherapy. 61
32173048 2020
26
Five-year survival decreases over time in patients with BRCA-mutated ovarian cancer: a systemic review and meta-analysis. 61
32522775 2020
27
The Wnt3a/β-catenin/TCF7L2 signaling axis reduces the sensitivity of HER2-positive epithelial ovarian cancer to trastuzumab. 61
32248976 2020
28
Population-based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high-grade serous ovarian cancer. 61
32546565 2020
29
SPTBN1 suppresses the progression of epithelial ovarian cancer via SOCS3-mediated blockade of the JAK/STAT3 signaling pathway. 61
32516133 2020
30
Highly expressed STAT1 contributes to the suppression of stemness properties in human paclitaxel-resistant ovarian cancer cells. 61
32516753 2020
31
Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium. 61
32555365 2020
32
miR-744-5p inhibits cellular proliferation and invasion via targeting ARF1 in epithelial ovarian cancer. 61
32558345 2020
33
Prognostic impact of p16 and p53 gene expressions in stage 1a epithelial ovarian cancer. 61
32550735 2020
34
Cytoplasmic VDR expression as an independent risk factor for ovarian cancer. 61
32572587 2020
35
Expressions and clinical significances of STAT3 and Grim19 in epithelial ovarian cancer. 61
32411570 2020
36
MR imaging of epithelial ovarian cancer: a combined model to predict histologic subtypes. 61
32535738 2020
37
Novel Molecular Targets for Tumor-Specific Imaging of Epithelial Ovarian Cancer Metastases. 61
32545676 2020
38
Low anterior resection syndrome (LARS) in ovarian cancer patients - A multi-centre comparative cohort study. 61
32304899 2020
39
Isolated lymph node recurrence in epithelial ovarian cancer: Recurrence with better prognosis? 61
32381349 2020
40
Utility of serum CA-125 monitoring in patients with ovarian cancer undergoing immune checkpoint inhibitor therapy. 61
32507515 2020
41
Improved Sonographic Detection of Epithelial Ovarian Cancer: New Concepts and Evolving Technology. 61
32511206 2020
42
Development of a decision aid for primary treatment of patients with advanced-stage ovarian cancer. 61
32276940 2020
43
Genome-wide Analysis of Common Copy Number Variation and Epithelial Ovarian Cancer Risk-Response. 61
32482638 2020
44
Efficacy and toxicity of prolonged pegylated liposomal doxorubicin use in women with recurrent epithelial ovarian cancer. 61
32499072 2020
45
Fertility-sparing treatment for early-stage epithelial ovarian cancer: Contemporary oncologic, reproductive and endocrinologic perspectives. 61
32500605 2020
46
Phase II clinical trial of metformin as a cancer stem cell-targeting agent in ovarian cancer. 61
32369446 2020
47
Residential segregation and overall survival of women with epithelial ovarian cancer. 61
32484923 2020
48
Frailty is a determinant of suboptimal chemotherapy in women with advanced ovarian cancer. 61
32518016 2020
49
Multivariable analysis of association of beta-blocker use and survival in advanced ovarian cancer. 61
32222327 2020
50
Non-epithelial ovarian cancer in Denmark - Incidence and survival over nearly 40 years. 61
32223987 2020

Variations for Ovarian Epithelial Cancer

ClinVar genetic disease variations for Ovarian Epithelial Cancer:

6 ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 PIK3CA NM_006218.4(PIK3CA):c.3140A>G (p.His1047Arg)SNV Pathogenic 13652 rs121913279 3:178952085-178952085 3:179234297-179234297
2 PIK3CA NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys)SNV Pathogenic 13655 rs104886003 3:178936091-178936091 3:179218303-179218303
3 PIK3CA NM_006218.4(PIK3CA):c.1636C>A (p.Gln546Lys)SNV Pathogenic/Likely pathogenic 13657 rs121913286 3:178936094-178936094 3:179218306-179218306

Expression for Ovarian Epithelial Cancer

Search GEO for disease gene expression data for Ovarian Epithelial Cancer.

Pathways for Ovarian Epithelial Cancer

GO Terms for Ovarian Epithelial Cancer

Sources for Ovarian Epithelial Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....